Literature DB >> 35024763

US Insurer Spending on Ivermectin Prescriptions for COVID-19.

Kao-Ping Chua1, Rena M Conti2, Nora V Becker3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35024763      PMCID： PMC8759024          DOI： 10.1001/jama.2021.24352

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   157.335


× No keyword cloud information.
  3 in total

1.  The Politicization of Ivermectin Tweets During the COVID-19 Pandemic.

Authors:  Marlon I Diaz; John J Hanna; Amy E Hughes; Christoph U Lehmann; Richard J Medford
Journal:  Open Forum Infect Dis       Date:  2022-06-06       Impact factor: 4.423

2.  Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients.

Authors:  Arman Shafiee; Mohammad Mobin Teymouri Athar; Omid Kohandel Gargari; Kyana Jafarabady; Sepehr Siahvoshi; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2022-06-13       Impact factor: 5.913

Review 3.  Outpatient Management of COVID-19: A Primer for the Dermatologist.

Authors:  Sonia Wang; Joel M Gelfand; Cassandra Calabrese
Journal:  Curr Dermatol Rep       Date:  2022-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.